Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017

Market: Pharmaceuticals and Healthcare

Global, 61 pages report, published by Global Markets Direct

Keywords : Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutic Products under Development, Key Players in Muscarinic Acetylcholine Receptor M4 (CHRM4) Therapeutics, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline Overview, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline, Muscarinic Acetylcholine Receptor M4 (CHRM4) Pipeline Assessment

Report ThumbnailJune-2017
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017

Summary

Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies. The latest report Muscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017, outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 1 and 6 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Amnesia, Amyotrophic Lateral Sclerosis, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Epilepsy, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Parkinson's Disease, Presbyopia, Rett Syndrome and Sialorrhoea.

Furthermore, this report also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indication, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Anavex Life Sciences Corp, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Pipeline by Karuna Pharmaceuticals Inc, H1 2017
  • Pipeline by NeuroHealing Pharmaceuticals Inc, H1 2017
  • Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • AstraZeneca Plc
  • Heptares Therapeutics Ltd
  • Karuna Pharmaceuticals Inc
  • NeuroHealing Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
  • (aceclidine + tropicamide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (ANAVEX-273 + donepezil hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline tartrate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANAVEX-273 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tropicamide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-0467154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-6000918 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
  • Featured News & Press Releases
  • May 22, 2017: Anavex Life Sciences Reports New Data for ANAVEX 2-73 in Neurodevelopmental Disorders Including Angelman Syndrome-Data Presented at Antiepileptic Drug Trials XIV 2017 Conference
  • May 19, 2017: Karuna Pharmaceuticals to Present KarXT Tolerability Proof-of-Concept Data for KarXT, A Novel Antipsychotic Agent Targeting the Muscarinic Receptors, at Two Upcoming Medical Meetings
  • Jan 19, 2017: Anavex Life Sciences Receives Grant From Rettsyndrome.org to Commence U.S. Phase 2 Trial in 2017
  • Dec 15, 2016: Karuna Pharmaceuticals and PureTech Health Announce Positive Results from Tolerability Proof-of-Concept Study of KarXT, Being Developed for Schizophrenia and Alzheimers
  • Dec 08, 2016: Anavex Life Sciences Announces 12-Month Data of ANAVEX 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s disease Patients
  • Nov 22, 2016: Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimers Disease
  • Sep 28, 2016: Anavex Compound to be Tested in Biogen Neurological Protection Model
  • Sep 22, 2016: Anavex Life Sciences Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease
  • Sep 12, 2016: Karuna Doses First Subject in Tolerability Proof-of-Concept Study of Lead Product Candidate
  • Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016
  • Jul 27, 2016: Anavex Presents 31-Week Efficacy Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer’s Patients at AAIC 2016
  • Jul 24, 2016: Anavex Presents 31-Week Safety Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients at AAIC 2016
  • Jul 12, 2016: Anavex to Present at the Alzheimer’s Association International Conference (AAIC) 2016
  • Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
  • Jun 06, 2016: Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

Please select a license type

Share

Related Products

Global Markets DirectMuscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017Product ThumbnailMuscarinic Acetylcholine Receptor M4 (CHRM4) - Pipeline Review, H1 2017, Industry ReportProduct #: 829007
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved